報價延遲最少15分鐘:2024/05/02 01:11 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.25 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.37/-8.80
|
|
企業價值
50.81M
|
| 資產負債 |
|
每股賬面淨值
2.42
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/02 01:11 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. |